Last reviewed · How we verify
Pancreatic Neuroendocrine Tumor
Approved treatments
- Zanosar · Teva
- Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Sutent · Pfizer
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT. - Sunitinib Malate · Pfizer
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET. - Afinitor · Central European Society for Anticancer Drug Research
- Sutent · Pfizer
Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression. - Streptozotocin · Hoffmann-La Roche
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pancreatic Neuroendocrine Tumor patent landscape — cliff calendar, originator estates, attackable patents
- Pancreatic Neuroendocrine Tumor treatment landscape brief
- Pancreatic Neuroendocrine Tumor treatment updates RSS
Frequently asked questions about Pancreatic Neuroendocrine Tumor
What drugs treat Pancreatic Neuroendocrine Tumor?
Tracked treatments include Zanosar, Afinitor, Sutent, Sunitinib Malate, Streptozotocin.
What is the treatment for Pancreatic Neuroendocrine Tumor?
Standard treatment for Pancreatic Neuroendocrine Tumor includes Zanosar, Afinitor, Sutent, Sunitinib Malate, Streptozotocin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pancreatic Neuroendocrine Tumor patent cliff · Pancreatic Neuroendocrine Tumor CI report
- Treatment: Zanosar · Teva
- Treatment: Afinitor · Novartis
- Treatment: Sutent · Pfizer
- Treatment: Sunitinib Malate · Pfizer
- Treatment: Afinitor · Central European Society for Anticancer Drug Research
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing